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ABSTRACT:
TSC2 (Tuberous sclerosis complex 2) is an important tumour suppressor gene, 
mutations within which are linked to the development of tuberous sclerosis and 
implicated in multiple tumour types. TSC2 protein complexes with TSC1 and blocks 
the ability of the Rheb (Ras homolog enriched in brain) GTPase to activate mTOR 
(mammalian target of rapamycin), a crucial signal transducer which regulates protein 
synthesis and cell growth. Here, we report the characterisation of a novel isoform 
of TSC2 which is under direct control of the ligand-activated androgen receptor. 
TSC2 isoform A (TSC2A) is derived from an internal androgen-regulated alternative 
promoter and encodes a 508-amino acid cytoplasmic protein corresponding to the 
C-terminal region of full-length TSC2, lacking the interaction domain for TSC1 and 
containing an incomplete interaction domain required for Rheb inactivation. Expression 
of TSC2A is induced in response to androgens and full-length TSC2 is co-ordinately 
down-regulated, indicating an androgen-driven switch in TSC2 protein isoforms. In 
contrast to the well-characterised suppressive effect on cell proliferation of full-
length TSC2 protein, both LNCaP and HEK293 cells over-expressing TSC2 isoform A 
proliferate more rapidly (measured by MTT assays) and have increased levels of cells 
in S-phase (measured by both Edu staining and FACS analysis). Our work indicates, 
for the first time, a novel role for this well-known tumour suppressor gene, which 
encodes an activator of cell proliferation in response to androgen stimulation.
INTRODUCTION
Androgens drive prostate growth and the 
development of prostate cancer (PCa), the most common 
male cancer, via the cognate androgen receptor (AR), 
which activates a number of known molecular switches 
[1-4]. The AR exerts its transcriptional effects by binding 
to DNA sequences termed androgen response elements 
(AREs) associated with androgen-regulated genes. A 
number of androgen-regulated genes and pathways have 
been identified in PCa, including cell cycle regulators, and 
biosynthetic, glucose uptake and glycolysis pathways, and 
the master regulators thereof such as calcium/calmodulin-
dependent protein kinase 2 (CAMKK2) [4].  
Using a transcriptome-wide approach, we recently 
demonstrated that androgens can also regulate expression 
of alternative mRNA isoforms [5], which might also 
mediate the cellular response to androgens, and have 
roles in clinical PCa. Alternative mRNA isoforms can 
have distinct functions in the cell, and there is emerging 
evidence to suggest that expression of specific splice 
isoforms derived from PCa-relevant genes, including 
the AR itself [6], can contribute to PCa biology [7]. 
We previously identified a novel and previously 
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uncharacterised mRNA isoform made from TSC2 
(Tuberous Sclerosis Complex 2) which is a direct and 
rapidly-activated target of the AR [5].
The TSC2 gene was initially identified in the 
development of tuberous sclerosis, a systemic disorder 
characterised by the development of benign hamartomas 
[8]. TSC2 protein forms a heterodimeric tumour 
suppressor complex with TSC1, which is at the crossroads 
of many different signalling pathways, and serves as a 
nexus for integrating extracellular growth factor signalling 
and nutritional availability [9, 10]. The TSC2 protein 
contains a GTPase-activating protein (GAP) domain 
and acts as a GTPase inactivating protein for Rheb (Ras 
homolog enriched in brain) [11]. Rheb acts downstream of 
TSC2 to activate mTOR (mammalian target of rapamycin) 
a crucial signal transducer which regulates protein 
synthesis and cell growth [12-14].
Since TSC2 is a direct and rapid target of the AR 
in PCa cells, we aimed to further characterise this novel 
TSC2 transcription unit in PCa.
RESULTS
A novel isoform of TSC2 protein is induced in 
response to androgens
To precisely identify the TSC2 transcriptional 
initiation site associated with androgen stimulation, we 
first carried out 5′ RACE using previously extensively 
verified RNA [5] derived from both steroid-deplete and 
androgen-treated LNCaP cells. We identified a novel 
androgen-regulated 5′ RACE product absent from steroid-
deplete cells. Sequence analysis of this 5′ RACE product 
indicated a transcript initiating upstream of TSC2 exon 32. 
We confirmed the location of this androgen-regulated 5′ 
end using RT-qPCR to monitor upstream and downstream 
transcription levels in both steroid-deplete and androgen-
treated LNCaP cells. The novel androgen-regulated mRNA 
isoform (which we termed TSC2 isoform A) contained 
a 5′ UTR upstream of a translational start codon at the 
beginning of exon 32, and was predicted to encode a 56 
kDa, 508 amino acid protein (Figure 1A,B,C). 
To test if TSC2A mRNA isoform is translated into 
protein we performed western blot analyses of protein 
extracted from LNCaP cells grown in androgen-deplete 
and androgen-stimulated cells. Antibodies specific to the 
C-terminus of TSC2 protein detected a shorter protein 
isoform of approximately the predicted size expected 
from translation of TSC2A (~56kDa), in addition to the 
expected full-length TSC2 protein (~200 kDa) in androgen 
treated cells. Corresponding to the C-terminal location 
of TSC2A in the full-length protein, this 56 kDa species 
was not detected by an antisera specific to the N-terminus 
of full-length TSC2 (Figure 1D,E,F). This result was 
observed in at least six independent experimental repeats. 
In addition to the androgen-regulated induction of TSC2A 
expression in LNCaP cells, we also observed a reduction 
in expression of full-length TSC2 protein as reported 
previously [15].
In order to confirm the specificity of the band 
corresponding to TSC2A we stably transfected LNCaP 
cells grown in full media with shRNAs targeting the full-
length TSC2 mRNA, but not the TSC2A isoform. The 
results showed clearly that despite the loss of full-length 
TSC2, a band corresponding to the TSC2A protein is still 
detected by the C-terminal antibody (Figure 1G). This 
band is absent when shRNA targeting both isoforms is 
used (Figure 1H). 
The specificity of the antibodies was confirmed 
further by detection of recombinant TSC2A in HEK293 
cells by the C-terminal but not the N-terminal antibody 
(Supplementary Figure A). We also cloned the open 
reading frame (ORF) of TSC2A into an expression vector, 
and used this to make stable LNCaP cell lines. Increased 
levels of TSC2A were detected in the stably expressing 
cell line compared with the control cell line (made with 
empty vector). The protein encoded by the ORF of TSC2A 
exactly co-migrated with the endogenous TSC2A protein 
in the control cell line, thus confirming the expected size 
of this protein in LNCaP cells (Supplementary Figure B).
TSC2 isoform A expression in PCa in vitro and in 
vivo
We analysed a panel of PCa cell lines using primers 
just upstream of the start of TSC2A (exon 30-31) and 
specific to the start of TSC2A (5’RACE), to determine 
the presence of TSC2A transcript. Expression of our 
5’RACE product relative to exons 30-31 was increased 
in the majority of PCa cell lines studied, indicating that 
expression of this novel mRNA isoform is not specific 
to LNCaP cells (Figure 2A). We next carried out western 
analysis of TSC2 protein expression in a panel of PCa 
tissues to determine if TSC2A protein is expressed within 
clinical prostate tumours. Using the C-terminal antibody, 
we detected a protein corresponding in size to full length 
TSC2 in two out of the six samples studied, both of which 
also expressed TSC2A (Figure 2B). 
TSC2 protein has been previously shown to localise 
to the cytoplasm, but can localise to the nucleus under 
some circumstances [16-19]. To determine the intracellular 
location of endogenous TSC2A protein, we performed 
sub-cellular fractionation of LNCaP cells, and analysed 
nuclear and cytoplasmic fractions by western blotting 
with the anti-TSC2 (C-terminal specific) antibody. These 
experiments demonstrated that TSC2A fractionated within 
the cytoplasmic compartment, similarly to the full-length 
TSC2 protein (Figure 2C). Furthermore, we performed 
indirect immunofluorescence using anti-FLAG antibody 
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Figure 1: Identification of a novel androgen regulated protein isoform encoded by the tumour suppressor gene TSC2 
in PCa cells. (A) A novel internal initiation site from the TSC2 gene was identified in 24-hour androgen stimulated LNCaP cells using 5′ 
RACE. First strand cDNA synthesis was primed using a gene-specific  primer to TSC2 exon 34 and a product was obtained for LNCaP cells 
treated with the synthetic androgen R1881 (A+), which was absent from steroid-depleted (SD) cells. (B) Visualisation of the sequenced 5′ 
RACE product on the UCSC genome browser indicated the androgen regulated TSC2 isoform  contained a novel 5′ UTR, with a start codon 
at the beginning of exon 32. (C) Real-time qPCR using primer pairs to specific exons of TSC2 confirmed the location of the androgen-
indued TSC2 internal 5’ end. (D) Detection of TSC2 isoforms in LNCaP cells using antibodies specific to the N- and C terminus of the 
protein revealed an androgen inducible band, named isoform A, of approximately 60kDa detectable using the C-terminal antibody (E) 
which was absent when the same samples were probed with the N-terminal antibody (F). Anti-p70-S6K was used as a control to confirm 
the response to androgens. Notably, as well as induction of TSC2A, there was also a reduction in full-length TSC2 protein levels following 
androgen treatment detectable by both TSC2 antibodies. Stable transfection of LNCaP cells with shRNA targeting full-length TSC2 mRNA 
but not TSC2A (labelled N-term shRNA) showed that although there is loss of the full-length protein, TSC2A is still present, indicating it is 
not a degradation product of the full-length protein (G). Stable transfection with shRNA targeting both isoforms (labelled C-term shRNA) 
resulted in the loss of both proteins, demonstrating the specificity of the C-terminal TSC2 antibody (H).
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to specifically study the intracellular localisation of the 
TSC2A isoform in LNCaP cell lines stably expressing 
TSC2A fused to the FLAG epitope. TSC2A-FLAG protein 
localised within the cytoplasm of these stably transfected 
LNCaP cells (Figure 2D).
TSC2 isoform A does not inhibit mTOR activation
Full-length TSC2 protein interacts with TSC1 to 
inhibit the activation of mTOR by Rheb. When TSC2 
protein is lost, (e.g. in tuberous sclerosis), mTOR 
remains constitutively activated to drive cell growth 
[20]. To confirm this effect in LNCaP cells, we used 
siRNA to deplete expression of full-length TSC2. We 
observed that siRNA-mediated reduction in full-length 
TSC2 expression was associated with increased mTOR 
activation, as evidenced by increased phosphorylation 
levels of S6K, which is downstream of mTOR (Figure 3A, 
lane 3). Conversely over-expression of full-length TSC2 
in HEK293 cells caused a decrease in phosphorylation 
levels of S6K (Figure 3B, lane 2). In contrast, when 
TSC2A was over-expressed in these cells, no change in 
phosphorylation of S6K was observed (Figure 3B, lane 
3), indicating that unlike full-length TSC2, TSC2A does 
not inhibit mTOR activation. We similarly monitored S6K 
status to test the activity of TSC2A protein expression on 
activity of the mTOR pathway in LNCaP cells. Although 
we could detect efficient expression of TSC2A in the 
stably-transfected cells by western blotting, no inhibition 
of the mTOR pathway was apparent both in the presence 
and absence of androgens (Figure 3D, lanes 3 and 6). 
TSC2 isoform A increases cell proliferation
To test if expression of the shorter TSC2A isoform 
might affect PCa cell proliferation, we monitored cell 
Figure 2: Expression of TSC2 isoform A is detected in clinical PCa samples and is a cytoplasmic protein. (A) Real-time 
qPCR using primer pairs to exons 30-31 and to the start of the 5’RACE product identified in Figure 1 were used to interigate the presence 
of TSC2A in a variety of PCa cell lines. An increase in the 5’RACE product relative to exons 30-31 in a number of cell lines was observed 
indicating detection of TSC2A transcript. (B) Both full-length and endogenous TSC2 isoform A were detected by western blotting in two 
clinical prostate tumour samples using the C-terminal antibody. (C) LNCaP cells were fractionated into nucleus (N) and cytoplasm (C) 
and analysed by SDS-PAGE and western blotting. Both endogenous TSC2 isoform A and full-length TSC2 were detected with the TSC2 
C-terminal antibody within the cytoplasmic fraction. Sam68 and β-tubulin were used as markers of the nucleus and cytoplasm respectively. 
(D) Flag-tagged TSC2A protein was ectopically expressed in LNCaP cells and detected in the cytoplasm by indirect immunofluorescence. 
DNA was detected by counterstaining with DAPI.
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growth of LNCaP cells either stably transfected with 
TSC2A or empty vector. In three independent experiments, 
cells stably expressing TSC2A exhibited a statistically-
significant increase in cell proliferation as compared with 
wild-type LNCaP cells as determined by MTT assays 
(Figure 3D). To confirm this result, we generated HEK293 
cells stably expressing tetracycline-inducible TSC2A. 
Consistent with the results in LNCaP cells, tetracycline-
induced expression of TSC2A increased cell proliferation 
in HEK293 cells (see Supplementary Figure Ci).  
We then monitored incorporation of EdU over a six 
hour period in LNCaP cells stably-expressing TSC2A. 
LNCaP cell populations expressing TSC2A exhibited 
significantly increased proportion of cells in S-phase as 
compared with wild-type controls (Figure 3E), a result 
which was confirmed by cell cycle analysis of DAPI 
stained cells where a corresponding decrease in the 
proportion of cells in G0/G1 was observed (Figure 3F). 
Similar results were seen in HEK293 cells expressing 
TSC2A (Supplementary Figure Cii, iii) confirming that 
Figure 3: TSC2 isoform A does not inhibit mTOR signalling and increases cell proliferation. (A) Knock-down of TSC2 
protein by siRNA depletion targeting the C-terminal of the protein causes an increase in mTOR signalling, as measured by changes in 
phosphorylation of S6K. (B) Conversely, over-expression of full-length TSC2 in HEK293 cells caused a reduction in S6K phosphorylation 
(lane 2), however unlike full-length TSC2 the TSC2A isoform does not inhibit mTOR activation (lane 3). (C) Over-expression of TSC2A in 
LNCaP cells did not inhibit mTOR signalling under both steroid-deplete and androgen treated conditions. Analysis of cell proliferation by 
(D) MTT assay and (E) incorporation of EdU over 6 hours indicated that expression of the TSC2A isoform increases LNCaP cell growth. 
(F) Similarly, cell cycle analysis of DAPI stained cells by flow cytometry shows that TSC2A decreases the percentage of cells in G1/G0 
and increases the percentage of cells in S phase. 
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TSC2A increases cell proliferation.
DISCUSSION
A number of oncogenes and tumour suppressor 
genes have been shown to have multiple promoters, and 
the aberrant use of promoters in some genes has been 
directly correlated to cancer initiation and progression 
[21, 22]. Technological advances in gene expression 
profiling and mapping of transcription factor binding  are 
able to identify androgen-dependent changes in promoter 
usage and alternative isoform expression which normally 
would not have been detected using standard 3’ end 
arrays [5]. These changes may yield functionally differing 
protein isoforms which may be important in mediating 
the androgenic response in prostate development and 
tumourigenesis. 
Here, we report the characterisation of a new 
isoform of the tumour suppressor gene TSC2 which is 
derived from an internal androgen-regulated alternative 
promoter and has potentially oncogenic activity. Androgen 
stimulation causes a switch in TSC2 protein isoform 
expression; expression of TSC2A is induced and full-
length TSC2 is co-ordinately down-regulated, with overall 
TSC2 expression levels remaining similar. Dutertre et al. 
2010 studied the use of alternative promoters (AP) in 
response to oestrogens and identified a number of cases 
where estradiol-regulated a switch in mRNA isoforms, 
without affecting the overall expression level of each 
gene [23]. Our findings indicate that AR may be regulating 
TSC2 isoform expression in a similar way, with significant 
functional consequences.
Down-regulation or loss of full-length TSC2 
has been shown to stimulate cell proliferation [24], 
whereas over-expression of TSC2 has been shown to 
have a suppressive role on cell proliferation in a variety 
of different cell types [25, 26]. In contrast, our results 
indicate that rather than having a suppressive role on cell 
growth, expression of TSC2 isoform A actually causes 
cells to proliferate more rapidly. These data suggest that 
the mitogenic effect of androgens in PCa cells may be 
mediated not only by the androgen-dependent reduction 
in full-length TSC2 expression (and subsequent effects 
on mTOR signalling), but also by an independent and 
novel effect mediated specifically by cytoplasmic TSC2A. 
Our results indicate that the shorter TSC2A protein itself 
does not act as an inhibitor of mTOR signalling and is 
consistent with an absent interaction domain for TSC1 and 
an incomplete Rheb interaction domain [27].  
The use of alternative promoters within the same 
gene to encode different mRNA isoforms, with one splice 
isoform acting as a tumour suppressor and an alternative 
isoform functioning as an oncogene, has been described 
previously. The RASSF1 (Ras association domain family 
1) gene is a Ras effector which encodes two major 
mRNA isoforms, RASSF1A and RASSF1C by alternative 
promoter selection and alternative splicing [28]. The 
RASSF1A isoform encodes a well-characterised tumour 
suppressor protein which is often epigenetically silenced 
in cancer [29, 30], whereas RASSF1C which is derived 
from an alternative promoter has been shown to stimulate 
proliferation and attenuate apoptosis in breast cancer 
cells  [28]. Our results suggest that full-length TSC2 and 
TSC2 isoform A may have similar opposing, antagonistic 
functions within cells with oscillations in expression of 
TSC2 isoforms influencing PCa cell growth in response 
to the AR (Figure 4). This may be of clinical significance 
as TSC2A expression may drive mTOR-independent cell 
growth, conferring resistance to mTOR inhibition as a 
therapy for clinical PCa.
MATERIALS AND METHODS
Antibodies: 
The following antibodies were used: anti-TSC2 
C-term rabbit polyclonal antibody (4308, Cell Signalling 
Technology), anti-TSC2 N-term rabbit polyclonal antibody 
(3635, Cell Signalling Technology), anti-p70-S6K (9234 
Cell Signalling Technology), anti-Sam68 rabbit polyclonal 
antibody (sc333 Santa Cruz Biotechnology), anti-actin 
rabbit polyclonal antibody (A2668, Sigma), anti-β-Tubulin 
mouse monoclonal antibody  (T5293, Sigma), anti-FLAG 
mouse monoclonal antibody (F3165, Sigma), normal 
rabbit IgG (711-035-152 Jackson labs) and normal mouse 
IgG (715-036-150 Jackson labs).
Figure 4: Model: Full-length TSC2 inhibits cell growth, 
whereas isoform TSC2A activates cell growth. In steroid-
deplete conditions full-length TSC2 acts in complex with TSC1 
to inhibit mTOR activation and have a negative effect on cell 
growth. In androgen stimulated cells expression of the full-length 
TSC2 protein is reduced and there is simultaneous induction of 
isoform TSC2A  both of which increase cell proliferation. 
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DNA Constructs: 
TSC2A was cloned into pCDNA5-flag (V6520-20, 
Invitrogen) using BamHI and XhoI, into pCDNA3.1+ 
(V790-20, Invitrogen) using BamHI and XhoI, and into 
pX3flag CMV 10 (E7658, Sigma) using EcoRI and 
BamHI. TSC2 Full length was cloned into pCDNA5-flag 
using BamHI and BclI. 
Cell Culture: 
All cells were grown at 37°C in 5% CO2. LNCaP 
cells (CRL-1740, ATCC) were maintained in RPMI-
1640 with L-Glutamine (PAA Laboratories, R15-
802) supplemented with 10% Fetal Bovine Serum 
(FBS) (PAA Laboratories, A15-101). Where indicated, 
medium was supplemented with 10% dextran charcoal 
stripped FBS (PAA Laboratories, A15-119) to produce 
a steroid-deplete medium. Cells were then cultured for 
72 hours, following which 10nM synthetic androgen 
analogue methyltrienolone (R1881) (Perkin–Elmer, 
NLP005005MG) was added (androgen) or absent (steroid-
deplete) for the times indicated. Stable LNCaP cell lines 
were generated by transfecting cells using Lipofectamine 
2000 (11668-027, Invitrogen), followed by selection with 
300µg/ml Geneticin (Invitrogen, 10131019) (reduced to 
150µg/ml following the death of untransfected cells) for at 
least four weeks. Flp-In™-293 cells (R750-07, Invitrogen) 
were maintained in DMEM GlutaMax (Invitrogen, 10566-
040), supplemented with 10% FBS (PAA Laboratories, 
A15-101) and stable cell lines generated using the Flp-
In T-Rex Core Kit (K6500-01, Invitrogen) according to 
the manufacturer’s instructions. Protein expression was 
induced using 1 µg/ml tetracycline (T7660, Sigma) for 72 
hours.
Clinical Samples: 
Full ethical approval was obtained for all human 
sample collections from the Northumberland, Tyne and 
Wear NHS Strategic Health Authority Local Research 
Ethics Committee (Ref: 2003/11). 
5’ Rapid amplification of cDNA ends: 
The identity of the 5’ end of the TSC2 isoform 
was determined using the 5’ RACE system for rapid 
amplification of cDNA ends (18374-058, Invitrogen) 
as per the manufacturer’s instructions and using 
the following gene specific primers: exon 33-34 
5’-AGGATTGGCTTGTTTGA-3’ and exon 32-33 
5’-AGGAGACGACTCGCTCGAT-3’. Following 
amplification, gel bands were purified with the QIAquick 
Gel Extraction kit (Qiagen, 28704), cloned using a 
CloneJET PCR Cloning Kit (Fermentas Life Sciences, 
K1231) and sequenced (Source Bioscience) using a T7 
sequencing primer.
RT-qPCR: 
Cells were harvested and total RNA extracted 
using TRIzol (Invitrogen, 15596-026) according to 
manufacturer’s instructions as previously described 
[31]. RNA was treated with DNase (Ambion) and 
cDNA was generated by reverse transcription of 1µg of 
total RNA using the Superscript VILO cDNA synthesis 
kit (Invitrogen, 11754-050). Quantitative PCR (qPCR) 
(Applied Biosystems 7900HT) was performed in 
triplicate on cDNA using SYBR® Green PCR Master Mix 
(Invitrogen, 4309155). Samples were normalised using the 
average of three reference genes, GAPDH, β –tubulin and 
actin. All primer sequences are listed in Supplementary 
Table 1.
siRNA: 
Knockdown of TSC2 was carried out using a 
pre-designed silencer select siRNA (Ambion S14437) 
and siPORT NeoFX transfection reagent (AM4510, 
Invitrogen). Scrambled silencer select siRNA was used as 
a control (Ambion). ShRNA: TSC2 N-term shRNA target 
sequence 5’-GAGCCCTCTTCTTTAAGGTCATC-3’ was 
cloned in pKLO.1. TSC2 C-term and scrambled shRNA 
plasmids were obtained from Addgene (plasmid 15478 
and 1864). Stable cell lines were generated by selecting 
cells with 0.5µg/ml puromycin and expanding single 
colonies.
Sub-cellular Fractionation:
Protein localisation within the cell was determined 
by fractionating cells to separate nuclear and cytoplasmic 
compartments as described previously [32].
Proliferation assays: 
MTT cell proliferation assay was carried out as 
per the manufacturer’s instructions (Cayman, 10009365) 
starting with 20000 cells (LNCaP) or 5,000 cells 
(HEK293) per well, with 9 replicates per sample. EdU 
incorporation was measued using the Click-iT® EdU 
Alexa Fluor® 488 Imaging Kit (Invitrogen, C10337) and 
counted using ImageJ. Additional cell cycle analysis was 
carried out using a CyStain® DNA 2 step kit (Partec UK, 
05-5005 ) and FACSCanto II (BD Biosciences). Results 
were analysed using ModFit under standard settings.
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